Moderate to severe plaque type psoriasis as defined at baseline by:. Other: UVB Excimer Laser Other: Narrowband UVB. Resource links provided by NLM:. Resource links provided by NLM:. Efficacy of ixekizumab in participants with moderate to severe chronic plaque psoriasis.
A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis. Resource links provided by NLM:. Information provided by (Responsible Party):. Purpose The purpose of this trial is to investigate the efficacy and safety of different doses and dose administrations of FP187 compared to a placebo treatment in patients with moderate to severe plaque psoriasis. Use of topical medical treatment or UVB treatment – Use of systemic anti-psoriatic treatment preceding the baseline visit Methotrexate, cyclosporine, steroids or PUVA treatment within x weeks; Biological treatment (efalizumab, adalimumab, infliximab, etanercept) within xx weeks; Acitretin within x months; Treatment with Fumaderm or other DMF containing products during past xx weeks prior to baseline visit; Discontinuation of previous treatment with Fumaderm or other DMF containing products due to lack of efficacy or side effects;. Moderate-to-severe psoriasis is managed by phototherapy and a range of systemic agents including traditional immunosuppressants such as methotrexate and cyclospsorin. Ultraviolet phototherapy interventions for plaque-type psoriasis. Indirect funding was provided to hospitals as part of global budgeting and resource allocation. Average annual cost per patient for NB-UVB phototherapy provided in the hospital, private clinic or at home was estimated to be 292, 810 and 365 respectively.
Treatment of moderate to severe plaque psoriasis with concomitant efalizumab and narrow-band ultraviolet B phototherapy. BACKGROUND: Efalizumab therapy and narrow-band ultraviolet B (NB-UVB) phototherapy have different mechanisms of action; combined therapy may be. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis. Resource links provided by NLM:. Willingness to hold sun exposure reasonably constant and to avoid use of tanning booths or other UV light sources during the study.
A Study Of The Efficacy And Safety Of Dfd-06 Cream In The Treatment Of Moderate To Severe Plaque Psoriasis
Subjects must have moderate to severe plaque psoriasis at the Baseline Visit. Chronic plaque psoriasis, the most common form of this disease, is characterized by scaly, erythematous, and infiltrated skin lesions, which are often pruritic and painful (Christophers and Mrowietz, 2003). 2010) One potential mediator of the stress and skin disease relationship is the role of the HPAA, which may be dysregulated in patients with chronic inflammatory diseases., 2002) Healthy subjects who underwent resource-oriented stress management training prior to an experimentally induced stress task had significantly attenuated cortisol responses and stress appraisals than controls (Storch et al. There is no cure for psoriasis, but many treatments exist to interrupt the overproduction of skin cells and to provide significant relief. She is the local principal investigator in a study studying the outcome and safety of the use of infliximab and golimumab in patients with chronic moderate to severe plaque psoriasis. The light therapy is an interesting angle because of course the best source of Vit D is UVB light. Resources Resources. Herbal medicines have been used to treat psoriasis for many years with anecdotal reports of efficacy which have attracted public attention. PUVA, UVB. Psoriatic plaque affect more than 20 of body surface area.